China Biopharmaceutical "Injection Hydrochloric Acid Idaby Star" was certified for drug registration.

Guide: IdaBi Star is a consistentrecommendation of a ml-bed therapy drugs at home and abroad.
on July 29, 2020, China Biopharmaceutical Co., Ltd. announced that the Group has developed a certificate of registration of drugs issued by the State Drug Administration of the People's Republic of China for the treatment of acute myeloid leukemia (AML) drug injection sedaticos (trademark name: Ambijian) (including 5mg and 10mg specifications) and is consistent with the quality and efficacy of generic drugs.
Idabi star is a consistentrecommendation of a number of AML cornerstone sistreatments at home and abroad.
, China Biopharmaceutical Group developed the first product of the same variety through consistency evaluation.
AML is a kind of aggressive and rapidly developing malignant tumor. If
is not treated in a timely manner, the patient will die of infection or bleeding within a few months of diagnosis.
IA (3-7) program consisting of Idarubicin in conjunction with Ara-C is a standard first-line solution for AML therapy and plays a cornerstone role in reducing or eliminating residual lesions and prolonging survival.
, Idabistar is an anti-tumor antibiotic with unique chemical structure, and the drug fat-soluble and anti-tumor activity is high, which is an important component of this classic treatment plan.
clinically proven that Idabistar is used in AML patients of different ages and at different risk stratifications, and is a guarantee of high remission and long-term survival, and the Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) recommend Edaby star for a full range of AML treatments.
the successful launch of AnbiJian will provide a better choice for more patients.
.